Case report: Reactive Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis and thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination and treated with intravenous immunoglobulin
Frontiers in Hematology · 2022
DOI: 10.3389/frhem.2022.983424 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Hematology, 2022. Verfasst von Yueh-Shih Chang und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology.
Abstract (Originalsprache)
Viral reactivation was previously reported after severe acute respiratory syndrome coronavirus‐2 (SARS-CoV-2) infection but was seldom documented after SARS-CoV-2 vaccination, except varicella-zoster virus and cytomegalovirus. Here, we present a case of reactive Epstein–Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) and thrombosis with thrombocytopenia syndrome after receiving SARS-CoV-2 mRNA vaccination. Antiplatelet factor 4 antibody was detected, and the bone marrow study showed hemophagocytosis and was positive in the immunohistochemistry staining for EBV-encoded small nuclear RNAs and negative staining for CD3 and CD56 markers of small lymphocytes. The high percentage of CD38 high /HLA-DR + cells among CD8 + T cells further confirmed HLH. After intravenous administration of immunoglobulin, the clinical symptoms, D-dimer level, fibrinogen, platelet count, EBV-DNA titer, and anti-PF4 level were all improved. Further investigation into the pathogenesis of vaccine-associated EBV reactivation, such as TNF-α, interleukin-1β (IL-1β), and interleukin-6 (IL-6), is warranted.
Förderung
- Ministry of Science and Technology
Zitieren
APA
Chang, Y., Ye, J., Cheng, T., Wen, Y., Huang, C. F., & Yeh, K. (2022). Case report: Reactive Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis and thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination and treated with intravenous immunoglobulin. Frontiers in Hematology. https://doi.org/10.3389/frhem.2022.983424
Vancouver
Chang Y, Ye J, Cheng T, Wen Y, Huang CF, Yeh K. Case report: Reactive Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis and thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination and treated with intravenous immunoglobulin. Frontiers in Hematology. 2022. doi:10.3389/frhem.2022.983424
BibTeX
@article{Chang2022,
author = {Chang, Yueh-Shih and Ye, Jung-Jr and Cheng, Tzu-Chien and Wen, Ying-Hao and Huang, Chi-Ying F. and Yeh, Kun-Yun},
title = {Case report: Reactive Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis and thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination and treated with intravenous immunoglobulin},
journal = {Frontiers in Hematology},
year = {2022},
doi = {10.3389/frhem.2022.983424}
}
EUVIMED